Delving into the Latest Updates on Morus Leaf Extract with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Morus indica L. Leaf Extract, Mulberry Leaf Extract

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperglycemia

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

University of Mississippi Medical Center

Active Organization

University of Chulalongkorn

Inactive Organization

University of Mississippi Medical Center

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Volunteers were divided into 2 groups: mulberry leaf extract capsule (DNJ 12mg) group and placebo group. They took the sample 3 times/day for 8 weeks. Complete blood count, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Fasting plasma glucose, HbA1c, and adverse effects were evaluated before and after 4 and 8 weeks.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Chulalongkorn

ISRCTN89882877

/ Active, not recruitingNot Applicable

A twelve-week randomised, placebo-controlled study on the effect of Reducose® on glucose, insulin, haemoglobin A1c, satiety, body composition, lipid profile, inflammatory markers and changes in gut microbiome in an overweight population. REMET (Reducose Metabolic Trial)

Start Date28 Oct 2024

Sponsor / Collaborator

Phynova Group Ltd.

[+1]

100 Clinical Results associated with Morus Leaf Extract

Login to view more data

100 Translational Medicine associated with Morus Leaf Extract

Login to view more data

100 Patents (Medical) associated with Morus Leaf Extract

Login to view more data

100 Deals associated with Morus Leaf Extract

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	United States	University of Mississippi Medical Center	01 Apr 2008
Hyperglycemia	Phase 1	Thailand	University of Chulalongkorn	01 Oct 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00795704 (Mul-DM, CTgov)	Phase 2/3	Diabetes Mellitus, Type 2	24	Placebo (Placebo)	kwqqmqmkfw(lgegdzyogv) = ldmzmfhtth mejviwabeb (xuvplcdbmb, 0.51) View more	-	09 Aug 2012
				Mulberry Leaf Extract (Mulberry Leaf Extract)	kwqqmqmkfw(lgegdzyogv) = bmnftfaigg mejviwabeb (xuvplcdbmb, 0.50) View more